Parkinson's disease (PD) is characterized by progressive and selective loss of dopaminergic neurons in substantial nigra pars compacta. Although the etiology remains unknown, there is considerable evidence that supports the view that programmed cell death (PCD) contributes, at least in part, to the degeneration of dopaminergic neurons in PD. Recent studies have identified a group of terminal caspases, particularly caspase-3/-7, as the central executive molecules in neuronal PCD. Caspase-3 actively participates in dopaminergic neuronal cell death in response to PD-relevant insults, although how caspase-3 is activated in this process is largely elusive. Furthermore, caspase-3 and other terminal caspases may not be the only executioners of neuronal PCD. A novel pro-apoptotic molecule, designated as AIF (apoptosis-inducing factor), has now been identified. AIF, which is activated and released from the mitochondria upon receiving death signals, and potently promotes high-molecular-weight DNA fragmentation and nuclear apoptosis. Bcl-2 family proteins are important PCD regulators and have been implicated in dopaminergic neuronal cell death. The pro-apoptosis Bcl-2 family member Bax is a well-characterized cell death effector, which, upon activation, targets mitochondria and triggers the cytochrome c-dependent intrinsic pathway. However, whether Bax activates AIF and the mechanism by which Bax is activated in dopaminergic neuronal apoptosis is unknown. We have now obtained exciting preliminary data which suggest that 1) caspase-3 activation in dopaminergic neurons is dependent on the intrinsic pathway; 2) both AIF-dependent and caspase-dependent mechanisms may contribute independently and synergistically to the final execution of dopaminergic neuronal apoptosis; 3) Bax is a direct mediator of AIF release in neurons, and the activation of Bax during dopaminergic cell death appears to be p53-dependent; and 4) Bak may be an important cofactor that enhances the pro-apoptotic effect of Bax at the mitochondria. Therefore, the objective of this project is to determine the role of caspase-3-dependent and AIF-dependent death execution pathways in dopaminergic neuronal cell death following PD-relevant insults and to determine the role of Bax in triggering the activation of these two pathways. The proposed studies will be performed using complementary in vitro and in vivo model systems, and will take advantage of our recent cloning of novel dominant-negative inhibitory mutants of caspase-9, Apaf-1 and AIF, and the availability of Bax-deficient mice. The following specific aims will be addressed: 1. Test the hypothesis that the caspase-9/Apaf-1 intrinsic pathway plays a central role in mediating terminal caspase activation and dopaminergic neuronal cell death following PD-relevant insults. 2. Test the hypotheses that AIF release is an important mechanism underlying caspase-independent dopaminergic cell death, and that AIF-dependent and caspase-3-dependent pathways work synergistically in the execution of cell death. 3. Test the hypotheses that Bax is a direct mediator for AIF release, and Bax contributes to dopaminergic cell death by activating both AIF-dependent and caspase-dependent pathways.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS044178-02
Application #
6703750
Study Section
Molecular, Cellular and Developmental Neurosciences 2 (MDCN)
Program Officer
Refolo, Lorenzo
Project Start
2003-04-01
Project End
2008-03-30
Budget Start
2004-04-01
Budget End
2005-03-31
Support Year
2
Fiscal Year
2004
Total Cost
$277,379
Indirect Cost
Name
University of Pittsburgh
Department
Neurology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Shen, Hongxia; Hu, Xiaoming; Liu, Can et al. (2010) Ethyl pyruvate protects against hypoxic-ischemic brain injury via anti-cell death and anti-inflammatory mechanisms. Neurobiol Dis 37:711-22
Vosler, Peter S; Chen, Jun (2009) Potential molecular targets for translational stroke research. Stroke 40:S119-20
Stetler, R Anne; Zhang, Feng; Liu, Collin et al. (2009) Ischemic tolerance as an active and intrinsic neuroprotective mechanism. Handb Clin Neurol 92:171-95
Vosler, Peter S; Graham, Steven H; Wechsler, Lawrence R et al. (2009) Mitochondrial targets for stroke: focusing basic science research toward development of clinically translatable therapeutics. Stroke 40:3149-55
Stetler, R A; Gao, Y; Signore, A P et al. (2009) HSP27: mechanisms of cellular protection against neuronal injury. Curr Mol Med 9:863-72
Signore, Armando P; Zhang, Feng; Weng, Zhongfang et al. (2008) Leptin neuroprotection in the CNS: mechanisms and therapeutic potentials. J Neurochem 106:1977-90
Yin, Wei; Signore, Armando P; Iwai, Masanori et al. (2008) Rapidly increased neuronal mitochondrial biogenesis after hypoxic-ischemic brain injury. Stroke 39:3057-63
Vosler, P S; Brennan, C S; Chen, J (2008) Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol Neurobiol 38:78-100
Wang, Suping; Xing, Zili; Vosler, Peter S et al. (2008) Cellular NAD replenishment confers marked neuroprotection against ischemic cell death: role of enhanced DNA repair. Stroke 39:2587-95
Zhang, Feng; Chen, Jun (2008) Leptin protects hippocampal CA1 neurons against ischemic injury. J Neurochem 107:578-87

Showing the most recent 10 out of 16 publications